Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $121.3 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 287.94% year-over-year to $121.3 million in Q1 2026; TTM through Mar 2026 was $495.3 million, a 176.43% increase from a year earlier, with the FY2025 full-year figure at $405.3 million, up 90.35% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $121.3 million, down from $152.9 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for JANX reached as high as $152.9 million in Q4 2025 and fell as low as $31.3 million in Q1 2025.
• Historically, Change in Acquisitions & Divestments has averaged $81.0 million across 5 years, with a median of $77.1 million in 2022.
• Across the five-year window, Change in Acquisitions & Divestments jumped 427.21% in 2022 and plunged 52.89% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $86.5 million in 2022, then slumped by 48.27% to $44.8 million in 2023, then rose by 29.61% to $58.0 million in 2024, then soared by 163.67% to $152.9 million in 2025, then slipped by 20.67% to $121.3 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $121.3 million in Q1 2026, $152.9 million in Q4 2025, and $126.4 million in Q3 2025.